Syntaxin’s TSI are novel recombinant proteins designed to exploit the unique pharmacology inherent in bacterial toxins
View how it works >
Syntaxin focuses its programmes in therapeutic areas where there is a high unmet need.
View Patient Focus >
Syntaxin has an alliance with Allergan, Inc. a world leader in the commercialisation of botulinum neurotoxin products to discover, develop and commercialise TSI for the treatment of pain in humans.
20 October 2011
Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics
Ipsen (Euronext: IPN, ADR: IPSEY) and Syntaxin, a biotechnology compan...
14 June 2011
Syntaxin and University School of Medicine, Geneva were awarded the Presidential Poster Prize at ENDO 2011, the Endocrine Society’s 13th Annual meeting held in Boston Mass 4-7th June 2011
...
BioTrinity 2012 24-26 April 2012. Newbury, UK
BioEquity Europe 2012 15-16 May 2012. Frankfurt, Germany